Actinium's ATNM-400 Shows Preclinical Activity in Therapy-Resistant Breast Cancer Models

• Actinium Pharmaceuticals will present preclinical ATNM-400 breast cancer findings at the San Antonio Breast Cancer Symposium on December 9, 2026.
• The investigational HER3-targeted alpha therapy demonstrated efficacy across treatment-resistant breast cancer subtypes, building on previously reported activity in other solid tumor models.
• The findings support broader evaluation across solid tumors, complementing ATNM-400's ongoing first-in-human clinical development in prostate cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY86224) on November 02, 2026, and is solely responsible for the information contained therein.